Evogene Ltd. is set to showcase its advancements in drug discovery at the upcoming BIO International Convention, scheduled for June 22-25, 2026, in San Diego, California.
The company, known for its innovative work in computational chemistry and AI-driven design of small molecules, will highlight its recent breakthroughs in pharmaceutical applications. Ofer Haviv, the CEO, along with Dr. Gabi Tarcic and Dr. Olga Nissan, will represent Evogene at the event. Dr. Tarcic is expected to present on the capabilities of ChemPass AI™, emphasizing its role in fostering collaborative drug development partnerships.
Evogene's presentation is scheduled for June 23, 2026, at 2:00 PM PT in Theater 1. The management team will also be available for individual meetings to discuss potential collaborations and innovations in drug discovery.
This engagement at the BIO International Convention underscores Evogene's commitment to integrating cutting-edge AI technology with real-world pharmaceutical challenges. As the industry increasingly leans on AI for drug development, Evogene's advancements could significantly impact how drugs are discovered and optimized, potentially accelerating the timeline for bringing new therapies to market.